Voyager Therapeutics, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016. Voyager is a clinical-stage gene therapy company developing AAV-based treatments for central nervous system diseases. It had no approved products or product-sale revenue; collaboration revenue came from Genzyme.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Collaboration revenue | $4.830 million | $2.576 million |
| Research and development expense | $8.732 million | $5.523 million |
| General and administrative expense | $3.565 million | $1.881 million |
| Total operating expenses | $12.297 million | $7.404 million |
| Operating loss | $7.467 million | $4.828 million |
| Net loss | $7.188 million | $14.577 million |
| Net loss per share, basic and diluted | $0.29 | $15.79 |
- Operating margin, calculated as operating loss divided by collaboration revenue, was approximately negative 155% versus negative 187%. Product gross margin is not applicable because Voyager had no product sales.
- Cash and cash equivalents were $33.895 million; marketable investments totaled $180.086 million. Combined cash, cash equivalents and marketable securities were approximately $214.0 million at quarter-end. Working capital was approximately $182.6 million.
- Operating cash flow was negative $9.487 million; investing cash flow was positive $12.069 million, primarily reflecting maturities of marketable securities; financing cash flow was positive $0.004 million. Cash increased $2.586 million during the quarter.
- Total liabilities were $56.383 million, including $50.633 million of deferred collaboration revenue. The filing reports no debt balance. Operating lease commitments totaled $30.672 million, including approximately $25.0 million associated with the lease extension and additional facility.
Changes versus the prior comparable period
- Revenue rose $2.254 million, or approximately 88%, reflecting recognition of Genzyme collaboration consideration for research and development services.
- Operating expenses increased $4.893 million, about 66%. R&D rose $3.209 million, largely from higher employee and contractor costs, platform and process development, and Genzyme in-kind services. G&A increased $1.684 million, including higher headcount and public-company costs.
- Net loss narrowed by $7.389 million, despite the larger operating loss. The primary reason was that Q1 2015 included $9.749 million of other expense, mainly a fair-value remeasurement loss on Series A preferred-stock tranche rights; no comparable expense occurred in Q1 2016. Q1 2016 also included $0.465 million of interest income.
- Per-share loss is not directly comparable: the IPO and preferred-stock conversion in November 2015 substantially increased common shares outstanding. Q1 2016 weighted-average shares were 25.1 million versus 1.0 million in Q1 2015.
Outlook, developments and risks
- Management expected existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2019, based on its then-current operating plan. It also expected significant expense growth and stated that additional funding would be needed to achieve its objectives; future financing may be unavailable or dilutive.
- The most advanced candidate, VY-AADC01 for advanced Parkinson’s disease, was in an open-label Phase 1b trial, with human proof-of-concept data targeted for Q4 2016. Voyager expected to submit an IND for its ALS program, VY-SOD101, in late 2017. These are stated targets, not guarantees.
- The Genzyme agreement includes options across several programs, potential option payments, milestones of up to $645 million in aggregate and tiered royalties, all contingent on future events. Q1 revenue was $4.830 million; $50.633 million remained deferred at March 31, 2016. Future milestone and royalty receipts are uncertain.
- Voyager disclosed serious risks typical of early-stage gene therapy development, including clinical failure, regulatory approval, manufacturing scale-up, competition, intellectual-property protection and reliance on future financing. It highlighted surgical risks for direct-to-brain administration; three patients in an earlier UCSF trial experienced procedure-related hemorrhages. In the ongoing VY-AADC01 trial, one patient experienced a pulmonary embolism and related arrhythmia determined to be related to the procedure and prolonged immobility, not the product.
- In January 2016, Voyager extended its existing Cambridge lease to December 2024 and agreed to lease an additional approximately 26,000 square feet, projected to be ready for occupancy in early 2017. Estimated lease payments under the relevant agreements were approximately $25.0 million.
- No litigation was reported. Management concluded disclosure controls and procedures were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether VY-AADC01 achieves the targeted Q4 2016 proof-of-concept milestone, and the complete safety and efficacy data from its trial.
- Whether the company’s spending and clinical progress remain consistent with the stated funding runway into 2019, including the impact of expanded facilities and lease obligations.
- Genzyme program progress, option exercise decisions, and the conditions and timing required for any milestone, royalty or additional collaboration revenue.
- Potential dilution from future capital raising and equity compensation; also note the significant share-count change following the IPO.
- Clinical, regulatory, manufacturing and competitive risks, including risks associated with neurosurgical administration and AAV gene therapy.